Next Article in Journal
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Next Article in Special Issue
Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?
Previous Article in Journal
SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment
Previous Article in Special Issue
Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer
Open AccessReview

Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target

1
Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL et Dermatologie (PNEU), Université catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
2
Division of Pneumology, Cliniques Universitaires St-Luc, UCL, 1200 Brussels, Belgium
3
Division of Pneumology, CHU UCL Namur (Godinne Site), UCL, 5530 Yvoir, Belgium
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(11), 1683; https://doi.org/10.3390/cancers11111683
Received: 15 September 2019 / Revised: 22 October 2019 / Accepted: 24 October 2019 / Published: 29 October 2019
(This article belongs to the Special Issue Targeted Therapy for Small Cell Lung Cancer)
Small-cell lung cancer (SCLC) represents 15% of all lung cancers and it is clinically the most aggressive type, being characterized by a tendency for early metastasis, with two-thirds of the patients diagnosed with an extensive stage (ES) disease and a five-year overall survival (OS) as low as 5%. There are still no effective targeted therapies in SCLC despite improved understanding of the molecular steps leading to SCLC development and progression these last years. After four decades, the only modest improvement in OS of patients suffering from ES-SCLC has recently been shown in a trial combining atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, with carboplatin and etoposide, chemotherapy agents. This highlights the need to pursue research efforts in this field. Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that is overexpressed and activated in several cancers, including SCLC, and contributing to cancer progression and metastasis through its important role in cell proliferation, survival, adhesion, spreading, migration, and invasion. FAK also plays a role in tumor immune evasion, epithelial-mesenchymal transition, DNA damage repair, radioresistance, and regulation of cancer stem cells. FAK is of particular interest in SCLC, being known for its aggressiveness. The inhibition of FAK in SCLC cell lines demonstrated significative decrease in cell proliferation, invasion, and migration, and induced cell cycle arrest and apoptosis. In this review, we will focus on the role of FAK in cancer cells and their microenvironment, and its potential as a therapeutic target in SCLC. View Full-Text
Keywords: focal adhesion kinase; small-cell lung cancer; targeted therapy focal adhesion kinase; small-cell lung cancer; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Aboubakar Nana, F.; Vanderputten, M.; Ocak, S. Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. Cancers 2019, 11, 1683. https://doi.org/10.3390/cancers11111683

AMA Style

Aboubakar Nana F, Vanderputten M, Ocak S. Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. Cancers. 2019; 11(11):1683. https://doi.org/10.3390/cancers11111683

Chicago/Turabian Style

Aboubakar Nana, Frank; Vanderputten, Marie; Ocak, Sebahat. 2019. "Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target" Cancers 11, no. 11: 1683. https://doi.org/10.3390/cancers11111683

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop